The Transient Appearance of Anti-GAD Antibody in a Type 2 Diabetic Patient with Empyema

Key words: anti-GAD antibody, diabetes mellitus, Streptococcus pneumoniae, infection, false positive

Glutamic acid decarboxylase (GAD) catalyzes the synthesis of the neurotransmitter GABA (γ-aminobutyric acid) and exists in two isoforms, GAD65 and GAD67. These proteins are 65% homologous, differing primarily in the amino terminal third of the protein, and can be found in brain and islet. GAD65 is predominantly expressed in human pancreatic β-cells and the presence of the anti-GAD65 antibody (GAD-Ab) is a predictor of the development of β-cell destruction. GAD-Ab has been detected in 70–80% of recently diagnosed type 1 diabetic patients and is a useful diagnostic marker of type 1 diabetes mellitus. Although type 1 diabetic patients remain positive for GAD-Ab for a long time (1), in type 2 diabetic patients it is rare for GAD-Ab to transiently convert to positive.

The present patient, a fisherman, was diagnosed with diabetes mellitus at the age of 20, but he was unable to come to our hospital on a regular basis. He was admitted to our hospital when he was 24 because of an injury to the right foot, for the following 3 years. On October 2, 2001, at the age of 27, he was admitted to our hospital again for high fever and right chest pain. There were moist rales and knock pain upon neurological examinations produced no abnormal findings. The radiograph of the patient’s chest showed an infiltrative shadow in the right lower lung field. Neurological examinations produced no abnormal findings. The white blood cell count was 21,400/mm³ (neutrophils 97.0%, monocytes 1.0%, lymphocytes 2.0%) and the C-reactive protein level was 42.6 µg/day. Results of both thyroid and microscopic tests were negative. The patient was diagnosed with type 2 diabetes mellitus and was given 2.5 mg per day of glibenclamide. However, glycemic control was poor with HbA1c remaining above 10% for the following 3 years. On November 14, 2001, HbA1c was 8.2% and u-CPR, 53.9 µg/day. Laboratory data after he was discharged from our hospital showed that GAD-Ab was less than 1.3 U/ml, insulin antibody level 4.6% (reference range: less than 10%), islet cell antibody level negative and IA-2 antibody level less than 1.0 U/ml.

There are a few cases in which GAD-Ab became positive after interferon treatment for hepatitis C virus chronic infection, and some of them showed a decrease in insulin secretion (2). In addition, it has been reported that viral infections such as rotavirus and coxsackie virus, may be associated with a risk for development of type 1 diabetes mellitus (3). Viral induction of autoimmunity is thought to occur by either bystander T-cell activation or molecular mimicry. It has been reported that Streptococcus pneumoniae type 3 encodes a protein highly similar to GAD65 (4), so that pneumococcal infection may be associated with the induction of GAD-Ab.

GAD-Ab disappeared after the treatment for empyema, while u-CPR did not decrease in the present patient. The transient appearance of GAD-Ab in our case may not be associated with the development of β-cell destruction. GAD-Ab can be found in other autoimmune diseases such as stiffman syndrome, autoimmune thyroid disease, in 6–10% of patients classified with type 2 diabetes, as well as in 1–2% of the healthy population (5). The GAD-Ab radioimmunoassay by “Cosmic” also showed a false-positive level of 1.2%. Cases positive for GAD-Ab thus need to be carefully followed up with an eye on the changes in this titer and for evaluation of insulin requirement.

Toshio KAHARA, Toshinari TAKAMURA, Hitoshi ANDO, Tsuguhio MISHI*, Kazutoshi KOMORI**, Nobuo OHYA*** and Ken-ichi KOBAYASHI

From the Department of Endocrinology and Metabolism (First Department of Internal Medicine), Kanazawa University Graduate School of Medical Science, Ishikawa, *the Department of Internal Medicine, Public Ushitsu Hospital, Ishikawa, **the Department of Surgery, Public Ushitsu Hospital, Ishikawa and ***the Division of Respiratory Disease, Department of Internal Medicine, Kanazawa Medical University, Ishikawa

Received for publication October 9, 2002; Accepted for publication March 5, 2003

Reprint requests should be addressed to Dr. Toshio Kahara, the Department of Endocrinology and Metabolism (First Department of Internal Medicine), Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641
References


